Cerebricon

Cerebricon was a specialized contract research organization (CRO) based in Kuopio, Finland, that focused on preclinical drug discovery services for central nervous system (CNS) disorders. The company provided advanced in vivo models and imaging techniques to evaluate the efficacy of potential therapeutics for conditions such as stroke, Alzheimer's, and Parkinson's disease. Founded in 2000 as a spin-off from the University of Kuopio, it established a reputation for high-quality neurological research and sophisticated MRI capabilities. In 2009, Cerebricon was acquired by Charles River Laboratories for approximately $12.6 million to bolster its CNS discovery portfolio. Today, its expertise and facilities are fully integrated into Charles River's global discovery services network.